NO DECISIONDismissed97% confidenceGPT-5.4 (OpenAI)
Question
Will the results be positive?
Found
Reviewed
Summary
No trial-specific efficacy readout is public yet. The sponsor said ALPHA3 was initiated in June 2024 with primary EFS readout expected in 2H 2026, and later 2025 materials still describe it as an ongoing trial-in-progress. Without results, the trial cannot be framed positive or negative.
Sources
Sponsorir.allogene.com
Allogene Therapeutics Initiates Pivotal Phase 2 Trial Investigating Cemacabtagene Ansegedleucel (cema-cel)
Sponsor announced ALPHA3 initiation. It said efficacy analyses were expected in 2026, with primary EFS data readout in 2H 2026; this is forward-looking, not a results release.
View source
Sponsorallogene.gcs-web.com
Allogene Therapeutics Announces ALPHA3 Trial-in-Progress Poster Presentation at ASH Annual Meeting
2025 sponsor update calls ALPHA3 an ongoing pivotal Phase 2 trial and a Trial-in-Progress poster, indicating no public efficacy outcome for this exact study yet.
View source